Skip header and navigation

Refine By

7 records – page 1 of 1.

Kala-azar in a four-year-old child 18 months after brief exposure in Malta.

https://arctichealth.org/en/permalink/ahliterature38106
Source
Acta Paediatr Scand. 1989 Jul;78(4):650-2
Publication Type
Article
Date
Jul-1989
Author
K. Ornvold
H. Carstensen
P. Magnussen
M H Nielsen
F K Pedersen
Author Affiliation
Department of Paediatric Pathology, Rigshospitalet, Unniversity Hospital, Copenhagen, Denmark.
Source
Acta Paediatr Scand. 1989 Jul;78(4):650-2
Date
Jul-1989
Language
English
Publication Type
Article
Keywords
Antimony Sodium Gluconate - therapeutic use
Child, Preschool
Denmark
Humans
Leishmaniasis, Visceral - diagnosis - drug therapy - transmission
Male
Malta
Abstract
A four-year-old Danish boy developed kala-azar 18 months after a holiday in Malta. Splenectomy, with liver biopsy, was performed six months after onset of symptoms because of hypersplenism, and the diagnosis of kala-azar was only made four months later, when the histopathological specimens were reviewed. Previous bone marrow biopsies did not show Leishmania. Treatment with sodium stibogluconate was successful. The development of kala-azar after one week's stay in an endemic area stresses the importance of including this potentially fatal disease in the differential diagnosis of cases presenting with fever, splenomegaly, and pancytopenia.
PubMed ID
2551125 View in PubMed
Less detail

[Malaria. Admissions to Blegdams Hospital and to the Department of Infectious Diseases of the Royal Hospital]

https://arctichealth.org/en/permalink/ahliterature38434
Source
Ugeskr Laeger. 1988 Aug 15;150(33):1975-8
Publication Type
Article
Date
Aug-15-1988

[Nosocomial pneumonia in an intensive care unit].

https://arctichealth.org/en/permalink/ahliterature221431
Source
Ugeskr Laeger. 1993 Mar 22;155(12):871-3
Publication Type
Article
Date
Mar-22-1993
Author
B L Røder
S L Nielsen
P. Magnussen
A. Engquist
N. Frimodt-Møller
Author Affiliation
Klinisk mikrobiologisk afdeling og intensiv afdeling R., Bispebjerg Hospital, København.
Source
Ugeskr Laeger. 1993 Mar 22;155(12):871-3
Date
Mar-22-1993
Language
Danish
Publication Type
Article
Keywords
Cross Infection - epidemiology - microbiology - mortality
Denmark - epidemiology
Disease Outbreaks
Humans
Intensive Care Units
Pneumonia - epidemiology - microbiology - mortality
Retrospective Studies
PubMed ID
8480384 View in PubMed
Less detail

Nosocomial pneumonia in an intensive care unit in a Danish university hospital: incidence, mortality and etiology.

https://arctichealth.org/en/permalink/ahliterature224652
Source
Scand J Infect Dis. 1992;24(1):65-70
Publication Type
Article
Date
1992
Author
S L Nielsen
B. Røder
P. Magnussen
A. Engquist
N. Frimodt-Møller
Author Affiliation
Department of Anaesthesiology, Bispebjerg Hospital, Copenhagen, Denmark.
Source
Scand J Infect Dis. 1992;24(1):65-70
Date
1992
Language
English
Publication Type
Article
Keywords
Aged
Bacterial Infections - epidemiology - microbiology - mortality
Cross Infection - epidemiology - microbiology - mortality
Denmark - epidemiology
Female
Hospitals, University - statistics & numerical data
Humans
Incidence
Intensive Care Units - statistics & numerical data
Male
Middle Aged
Pneumonia - epidemiology - microbiology - mortality
Retrospective Studies
Risk factors
Abstract
We studied the patients admitted to the ICU at a Danish university hospital during 1 year with respect to nosocomial pneumonia (NP). Among 242 patients, who stayed more than 48 h, 23 (10%) developed NP. Patients with NP had significantly higher mortality (43% vs. 19%, p less than 0.05), longer median stay (276 h vs. 99 h, p less than 0.05) and a longer median intubation period (256 h vs. 74 h, p less than 0.05). In the NP group surgical patients were overrepresented as compared to medical patients (74% vs. 45%, p less than 0.05). Thoracotomy, treatment with H-2 blockers and immunosuppression represented significant risk factors. Considering the etiology, Enterobacteriaceae and Pseudomonas aeruginosa constituted 43% of the cases in strong contrast to the low frequency of these pathogens in community-acquired pneumonia. NP in the ICU patient is a resource consuming disease associated with a high mortality (43%), which is related to the frequent severe underlying diseases of these patients.
Notes
Comment In: Scand J Infect Dis. 1992;24(4):555-61411324
PubMed ID
1589727 View in PubMed
Less detail

[Occurrence of complement defects in meningococcal disease: who should be examined?].

https://arctichealth.org/en/permalink/ahliterature226508
Source
Ugeskr Laeger. 1991 Apr 15;153(16):1113-6
Publication Type
Article
Date
Apr-15-1991
Author
H E Nielsen
P. Magnussen
I. Lind
Author Affiliation
Statens Seruminstitut, København.
Source
Ugeskr Laeger. 1991 Apr 15;153(16):1113-6
Date
Apr-15-1991
Language
Danish
Publication Type
Article
Keywords
Complement System Proteins - deficiency - genetics
Humans
Meningitis, Meningococcal - genetics - immunology
Neisseria meningitidis - classification - immunology
Recurrence
Scandinavia - epidemiology
Serotyping
Abstract
Congenital complement deficiency states occur very rarely. These deficiencies are associated with a high risk of meningococcal disease (MD). We suggest that the following groups of individuals with MD are examined for complement deficiencies: 1. Individuals belonging to families, in which more than one case of MD has occurred with an interval exceeding one month. 2. Individuals infected with the low-virulent meningococcal serogroups W-135, 29E, X, Y, Z. 3. Individuals with recurrent MD. Since properdin deficiency probably is the most common deficiency associated with MD it is important that the screening includes the alternative complement pathway.
PubMed ID
1902602 View in PubMed
Less detail

[Treatment of hydatidosis with albendazol].

https://arctichealth.org/en/permalink/ahliterature229999
Source
Ugeskr Laeger. 1989 Oct 23;151(43):2791-4
Publication Type
Article
Date
Oct-23-1989
Author
P. Magnussen
R. Gelletlie
I C Bygbjerg
Source
Ugeskr Laeger. 1989 Oct 23;151(43):2791-4
Date
Oct-23-1989
Language
Danish
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Albendazole - therapeutic use
Anthelmintics - therapeutic use
Denmark
Echinococcosis - drug therapy
Echinococcosis, Hepatic - drug therapy
Emigration and Immigration
Female
Humans
Male
Abstract
Eight patients with hydatidosis treated with albendazol in daily doses of 10 mg/kg daily in courses of 28 days (4-6 courses) were analysed. The patients came from Morocco, Spain, Turkey and Yugoslavia. Seven patients had a cyst (or cysts) in the liver and one had also cysts in the kidneys. One patient had cysts in the muscles of the extremities. As assessed by ultrasonic scanning, computed tomography of the cysts, general condition, serology and the presence of hydatid antigen in the serum, treatment was effective in six patients. One patient developed an allergic reaction to albendazol. All of the patients had varying degrees of liver involvement which were reversible. Neutropenia did not occur. Various parameters for assessing the therapeutic effect are mentioned. Albendazol appears to be effective in the treatment of non-operable hydatid disease and to prevent recurrence after surgery.
PubMed ID
2588356 View in PubMed
Less detail

Treatment of Plasmodium falciparum malaria with mefloquine alone or in combination with i.v. quinine at the Department of Communicable and Tropical Diseases, Rigshospitalet, Copenhagen 1982-1988.

https://arctichealth.org/en/permalink/ahliterature37479
Source
Dan Med Bull. 1990 Dec;37(6):563-4
Publication Type
Article
Date
Dec-1990
Author
P. Magnussen
I C Bygbjerg
Author Affiliation
Department of Communicable and Tropical Diseases, Rigshospitalet, Copenhagen.
Source
Dan Med Bull. 1990 Dec;37(6):563-4
Date
Dec-1990
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aged
Animals
Child
Child, Preschool
Denmark
Drug Therapy, Combination
Follow-Up Studies
Humans
Infant
Malaria - drug therapy
Mefloquine - adverse effects - therapeutic use
Middle Aged
Plasmodium falciparum - drug effects
Quinine - therapeutic use
Abstract
At the Department of Communicable and Tropical Diseases, Rigshospitalet, Denmark, mefloquine has been used since 1982 for the treatment of patients with suspected or verified chloroquine and sulfadoxine-pyrimethamine resistant P. falciparum malaria. Eighty-one patients treated with mefloquine are reviewed. Forty patients had complicated malaria; 18 were initially treated with IV quinine. Mefloquine dose for adults was 1,500 mg in one dose or divided in two with six hourly intervals. Mild gastrointestinal side effects were common; in 10 patients, the medication had to be repeated because of vomiting. No neurological or neuropsychiatric side effects were recorded in relation to treatment or during the follow up period (30 days). Temperature subsided with a mean of 2.7 days after initiation of treatment and trophozoites cleared with a mean of 3.6 days. One patient had recrudescence. Mefloquine is found safe and effective for the treatment of P. falciparum malaria and is recommended for treatment of worldwide acquired P. falciparum malaria, although patients should be monitored closely to disclose resistance.
PubMed ID
2073860 View in PubMed
Less detail

7 records – page 1 of 1.